

**TCTR ID : TCTR20190806004**

**Overall Recruitment Status : Recruiting**

**OTHER ID :**

**Retrospective registration**  
**This protocol was registered after enrollment of the first participant.**

---

**Tracking Information**

First Submitted Date : 06 August 2019  
First Posted Date : 06 August 2019  
Last Update Posted Date : 01 October 2019

---

**Title**

Public Title : Southeast Asia Malaria Research Center: Malaria epidemiology study in Thailand and Myanmar - A supplement Program for Malaria Elimination Strategy  
Acronym : MPPT  
Scientific Title : Southeast Asia Malaria Research Center: Malaria epidemiology study in Thailand and Myanmar - A supplement Program for Malaria Elimination Strategy  
Sponsor ID/ IRB ID/ EC ID : TMEC 19-034  
Registration Site : Thai Clinical Trials Registry  
URL : <https://www.thaiclinicaltrials.org/show/TCTR20190806004>  
Secondary ID : None

---

**Ethics Review**

1. Board Approval : Submitted, approved  
Approval Number : MUTM 2019-044-01  
Date of Approval : No Data  
Board Name : Ethics Committee of the Faculty of Tropical Medicine, Mahidol University  
Board Affiliation : Faculty of Tropical Medicine, Mahidol University  
Board Contact : Business Phone : +66 2 3549100-4 Ext. 1349 and 16  
Business Email : pornpimon.ada@mahidol.ac.th  
Business Address : 4th Floor, The 60th Anniversary of His Majesty the King's Accession to the Throne Building, Faculty of Tropical Medicine, Mahidol University 420/6 Ratchawithi Road, Ratchathewi, Bangkok 10400, Thailand

---

**Sponsor**

Source(s) of Monetary or Material Supports : US National Institute of Health  
Study Primary Sponsor : Faculty of Tropical Medicine, Mahidol University  
Responsible Party : Name/Official Title : Assoc. Prof. Jaranit Kaewkungwal  
Organization : Faculty of Tropical Medicine, Mahidol University  
Phone : +66 87 1001951 Ext. No Data  
Email : jaranitk@biophics.org  
Study Secondary Sponsor : None

---

**Protocol Synopsis**

Protocol Synopsis : The Greater Mekong Subregion (GMS) has set the strategic goal to eliminate malaria by 2030. Specifically, Thailand and Myanmar aim to be malaria-free by 2024 and 2030, respectively. Though GMS countries have strong political commitment to put intensive efforts to reach this goal, there are significant challenges requiring innovative strategies tailored to the whole region. One particular problem is that Plasmodium vivax has become the predominant species in the GMS. Malaria control histories have shown the extreme resilience of P. vivax to control measures. Mass drug administration (MDA) has played critical roles in many malaria eradication campaigns in the past. However, concerns exist with regard to its efficacy, sustainability, operational feasibility, and fear of accelerating drug resistance. Chloroquine/primaquine (CQ/PQ) remains effective and the frontline treatment for vivax malaria in the GMS despite sporadic reports of CQ-resistant P. vivax. Although mass primaquine preventive treatment (MPPT) has been successfully carried out to reduce and eliminate temperate zone P. vivax, it has not been evaluated in tropical countries. The goal of this study, which is a supplement program to the ICEMR Project supported by NIH, is to thoroughly assess effectiveness, feasibility, sustainability, acceptability and community engagement of MPPT as a strategy for malaria elimination in Thailand and Myanmar. To realize this central goal, two integrated studies are proposed, which leverage the overall infrastructure, collaboration network, and data

management plan of the current ICEMR program.

I. Observational Study: Assessing the acceptability of malaria interventions: a mixed method. This study aims to assess the acceptability and operational feasibility of implementing MPPT and enhanced vector-control interventions in malaria endemic villages as well as the readiness of the community and health providers for malaria elimination.

This study will collect information from 500 healthcare personnel and 1,500 adults in malaria endemic provinces including, but not limited to, 5 provinces/townships including Yala, Narathiwat, Tak, Ubon Ratchathani and Sisaket in Thailand; and Ban Mauk townships in Myanmar. In-depth interview and focus-group discussion will be performed to assess the acceptability, feasibility and readiness of conducting MPPT in malaria endemic communities and to assess public awareness, readiness and ability of existing healthcare facilities for malaria elimination in both countries. In addition, the study will assess the acceptability and feasibility of implementing enhanced vector-control interventions in endemic communities considering elimination.

II. Implementation Study: Cost-effectiveness of MPPT to accelerate malaria elimination in Southeast Asia. The specific objectives are to assess impact of MPPT on malaria transmission.

1. To conduct a cluster-randomized control trial to evaluate effectiveness of MPPT augmented to national standard of care to inform malaria elimination effort.

2. To conduct preparatory activities such as surveillance, community sensitization, and stakeholder engagement for potential scale-up.

We will conduct an implementation study to evaluate effectiveness, safety, and feasibility of MPPT in malaria communities in Thailand and Myanmar. A cross-over clustered-randomized controlled trial will be conducted in 6 clusters in Thailand and 4 clusters in Myanmar, with the total population of approximately 4,000 (2,000 in each country). The program impact will be monitored and evaluated at the human, vector, and parasite population levels. In the study, we will also prepare the target communities for potential large-scale MPPT implementation if the MPPT proved a success. Activities will include sensitizing and engaging with stakeholders including MOPH, provincial (township) authorities, operational units, and communities, and setting up passive surveillance in the future sites to provide baseline data to inform treatment allocation in possibility to scale up to the regional level. We will determine the cost-effectiveness of adding MPPT to routine national control activities to eliminate reservoirs of malaria.

URL not available

---

#### Health Conditions

Health Condition(s) or Problem(s) Studied : Malaria

Keywords : Malaria elimination Vivax malaria Mass primaquine preventive treatment

---

#### Eligibility

Inclusion Criteria : For Observational study:

1. Both male and female
2. Age 18 years old or above

For Implementation study:

1. Both male and female
2. Age 1 year old or above

Gender : Both

Age Limit : Minimum : 1 Years Maximum : 0 N/A (No limit)

Exclusion Criteria : For Observational study:

1. Not willing to participate in the study
2. Unable to provide information either due to physical or mental conditions

For Implementation study:

Regarding participating in cohort

1. Not willing to participate in the study
2. Mental Illness and prisoners

Regarding drug administration:

1. Not willing to take primaquine
2. Pregnant and lactating women
3. For those age 7 years or older who has G6PD abnormal
4. Have history of allergy to primaquine
5. Have history of drug reaction, such as hemolysis or dark urine, after having primaquine

Accept Healthy Volunteers : Yes

---

---

**Status**

Overall Recruitment Status : Recruiting

Key Trial Dates	Study Start Date (First enrollment) : 17 July 2019	Indicate Type : Actual
	Completion Date (Last subject, Last visit) : 31 March 2021	Indicate Type : Anticipated
	Study Completion Date : 31 July 2021	Indicate Type : Anticipated

---

**Design**

Study Type : Interventional  
Primary Purpose : Prevention  
Study Phase : N/A  
Intervention Model : Crossover  
Number of Arms : 2  
Masking : N/A  
Allocation : Randomized  
Control : Placebo  
Study Endpoint Classification : Safety/Efficacy Study  
Sample size  
Planned sample size : 4000

Intervention Arm 1  
Intervention name : Mass Primaquine Preventive Treatment (MPPT)  
Intervention Type : Experimental  
Intervention Classification : Drug  
Intervention Description : A dose of 0.25-0.50 mg/kg of PQ will be administered daily for 14 days to all volunteers in Group 1 (who will receive PQ treatment in Year 1) aged 7 years and above with a normal G6PD test result. Volunteers in Group 1 will be switched and not receive any treatment in Year 2.

Intervention Arm 2  
Intervention name : Control group  
Intervention Type : No Intervention  
Intervention Classification : No treatment  
Intervention Description : Volunteers in Group 2 will not receive PQ in Year 1 but will be switched and receive PQ for 14 days in Year 2.

---

**Outcome****Primary Outcome**

1. Outcome Name : Reduction in malaria incidence  
Metric / Method of measurement : a) The clinical malaria incidence rates, b) the Plasmodium prevalence rates  
Time point : Year 1 = Month 1, Month 5 and Month 9; Year 2 = Month 1, Month 5 and Month 9; Passive Case Detection

2. Outcome Name : Cost estimates for MPPT implementation  
Metric / Method of measurement : Costs spent for intervention and additional MPPT activities  
Time point : Monthly/Real time

**Secondary Outcome**

1. Outcome Name : Baseline prevalence of G6PD deficiency in the study population  
Metric / Method of measurement : G6PD-RDT  
Time point : Prior to PQ administration for each group

2. Outcome Name : Rates of primaquine-induced hemolysis in females  
Metric / Method of measurement : Hemoglobin level  
Time point : Day 1, 2, 4, 6, 7 and 28 of PQ treatment

3. Outcome Name : Impact of MPPT on parasite genetic diversity and relapse rates  
Metric / Method of measurement : Genotyping by deep sequencing of malaria parasites  
Time point : Year 1 = Month 1, Month 5 and Month 9; Year 2 = Month 1, Month 5 and Month 9; Passive case detection

4. Outcome Name : Morbidity data

Metric / Method of measurement : Monthly morbidity data of reportable diseases from the surveillance system

Time point : 6-month prior to MPPT (PQ administration), during 1st and 2nd MPPT, 6-month after MPPT intervention

**Location**

**Section A : Central Contact**

Central Contact First Name : Assoc. Prof. Jaranit Middle Name : Last Name : Kaewkungwal  
Degree : PhD Phone : +66 87 1001951 Ext. : No Data Email : jaranitk@biophics.org

Central Contact Backup First Name : Jetsumon Middle Name : Lastname : Prachumsri  
Degree : PhD Phone : +66 2 306 9187 Ext. : No Data Email : jetsumon.pra@mahidol.edu

**Section B Facility Information and Contact**

1. Site Name : Faculty of Tropical Medicine, Mahidol University  
City : No Data State/Province : Bangkok Postal Code : 10400  
Country : Thailand Recruitment Status : Recruiting

**Facility Contact** First Name : Assoc. Prof. Jaranit Middle Name : Last Name : Kaewkungwal  
Degree : PhD Phone : +66 87 1001951 Ext. : No Data Email : jaranitk@biophics.org

**Facility Contact Backup** First Name : Jetsumon Middle Name : Last Name : Prachumsri  
Degree : PhD Phone : +66 2 306 9187 Ext. : No Data Email : jetsumon.pra@mahidol.edu

**Investigator Name** First Name : Assoc. Prof. Jaranit Middle Name : Last Name : Kaewkungwal  
Degree : PhD Role : Principal Investigator

2. Site Name : University of Public Health  
City : No Data State/Province : Postal Code :  
Country : Myanmar Recruitment Status : Recruiting

**Facility Contact** First Name : Dr. Pyae Middle Name : Lin Last Name : Aung  
Degree : MBBS, MPH Phone : Ext. : No Data Email : pyaelinnag@gmail.com

**Facility Contact Backup** First Name : Dr. Myat Middle Name : Thu Last Name : Soe  
Degree : MBBS, IADCS, IDCS, DTM&H, MCTM, PhD Phone : Ext. : No Data Email : dr.myatthusoe@gmail.com

**Investigator Name** First Name : Dr. Than Middle Name : Naing Last Name : Soe  
Degree : MBBS, DAP&E, MPH, FETP Role : Site Sub-Investigator

**Section C : Contact for Public Queries (Responsible Person)**

First Name : Assoc. Prof. Jaranit Middle Name : Last Name : Kaewkungwal  
Degree : PhD Phone : +66 87 1001951 Ext. : No Data Email : jaranitk@biophics.org

Postal Address : 420/6 Ratchawithi Road, Ratchathewi  
State/Province : Bangkok Postal Code : 10400  
Country : Thailand Official Role : Study Principal Investigator  
Organization Affiliation : Faculty of Tropical Medicine, Mahidol University

**Section D : Contact for Scientific Queries (Responsible Person)**

First Name : Assoc. Prof. Jaranit Middle Name : Last Name : Kaewkungwal  
Degree : PhD Phone : +66 87 1001951 Ext. : No Data Email : jaranitk@biophics.org

Postal Address : 420/6 Ratchawithi Road, Ratchathewi  
State/Province : Bangkok Postal Code : 10400  
Country : Thailand Official Role : Study Principal Investigator  
Organization Affiliation : Faculty of Tropical Medicine, Mahidol University

**Deidentified Individual Participant-level Data Sharing**

Plan to share IPD : No Data  
Plan description : No Data

---

**Publication from this study**

MEDLINE Identifier : No Data

URL link to full text publication : No Data

---